Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article - ScienceDirect
Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection - eBioMedicine
Anti-Spike Protein Assays to Determine SARS-CoV-2 Antibody Levels: a Head-to-Head Comparison of Five Quantitative Assays | Microbiology Spectrum
Anti-Spike Protein Assays to Determine SARS-CoV-2 Antibody Levels: a Head-to-Head Comparison of Five Quantitative Assays | Microbiology Spectrum
Predicting the protective humoral response to a SARS-CoV-2 mRNA vaccine
WHO standards for COVID-19 established by the ECBS in Dec 2020
Is WHO International Standard for Anti-SARS-CoV-2 Immunoglobulin Clinically Useful?
Validation and performance of a multiplex serology assay to quantify antibody responses following SARS‐CoV‐2 infection or vaccination - Wilkins - 2022 - Clinical & Translational Immunology - Wiley Online Library
Dynamic trend to seropositivity for each IgG in 218 samples from 46... | Download Scientific Diagram
Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection - eBioMedicine
Evaluation of Commercial Anti-SARS-CoV-2 Antibody Assays and Comparison of Standardized Titers in Vaccinated Health Care Workers | Journal of Clinical Microbiology
Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection - eBioMedicine
Predicting the protective humoral response to a SARS-CoV-2 mRNA vaccine
Improvements and limits of anti SARS-CoV-2 antibodies assays by WHO (NIBSC 20/136) standardization
The comparability of Anti-Spike SARS-CoV-2 antibody tests is time-dependent: a prospective observational study | medRxiv
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection | Nature Medicine
Predicting the protective humoral response to a SARS-CoV-2 mRNA vaccine
Vaccines | Free Full-Text | Robust SARS-CoV-2 Antibody Responses in Asian COVID-Naïve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 Vaccine
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection | Nature Medicine
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection | Nature Medicine
Frontiers | IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10 Months After BNT162b2 Vaccination Than After SARS-CoV-2 Infection in Healthcare Workers
Quantitative measurement of IgG to SARS‐CoV‐2 antigens using monoclonal antibody‐based enzyme‐linked immunosorbent assays - Sander - 2022 - Clinical & Translational Immunology - Wiley Online Library
